We've pinpointed four major biotech catalysts this month, with Ameluz®PDT showing an impressive Probability of Approval (PoA) of 89%. As crucial dates in July and August approach, investors should pay attention to upcoming data releases and regulatory decisions that could influence the market. With seven catalysts on our list, each offers distinct opportunities and risks.

The full biotech catalysts to watch

Ameluz®PDT: A High-Probability Therapy for Superficial Basal Cell Carcinoma

Ameluz®PDT, from Biofrontera Inc. (BFRI), leads the charge in treating superficial basal cell carcinoma (sBCC) with a notable PoA of 89%. This photodynamic therapy combines 10% aminolevulinic acid (ALA) gel and red-light illumination, precisely targeting sBCC lesions while sparing healthy tissue. Trial results are striking, showing a 65.5% clearance rate for Ameluz versus 4.8% for placebo (p<0.0001), underscoring its efficacy. The global market for sBCC treatments is pegged at $1.2 billion. Ameluz's strong safety profile and minimal adverse events enhance its commercial appeal. The PDUFA date on September 28, 2026, will be crucial for its market entry. While the competitive landscape, including new non-surgical therapies, poses challenges, Ameluz's robust efficacy data positions it as a strong first-in-class contender.

Zervimesine (CT1812): Navigating the Challenges of DLB Psychosis

Zervimesine (CT1812) by Cognition Therapeutics (CGTX) stands as a potential advancement for dementia with Lewy bodies (DLB) psychosis, currently in Phase 2 trials with a PoA of 22.5%. The Phase 2 SHIMMER study pointed to positive trends in neuropsychiatric symptoms and caregiver distress, though the lack of definitive statistical significance is a concern. With the global DLB treatment market valued at $8.5 billion, there's a significant unmet need, as no FDA-approved meds specifically target DLB psychosis. The company plans a Phase 3 trial focusing on the 100 mg dose, with results crucial for success. Investors should watch for the FDA meeting minutes from May 2026 and the Phase 3 trial design announcement, both of which could impact Zervimesine's approval chances in this tough market.

CT-95 (MSLN x CD3): Early-Stage Risks in Solid Tumors

CT-95, a pioneering T cell engager bispecific antibody from Context Therapeutics (CNTX), is in Phase 1a trials for solid tumors, with a PoA of 18.5%. The global market for MSLN-expressing cancers is about $15 billion, offering a big opportunity due to poor survival rates and few effective therapies. However, the drug's current status carries risks, including a -60.8% run-up before the expected data release in September 2026. The lack of regulatory designations and challenges seen with other T cell engagers add to the uncertainty around CT-95. Investors should closely watch the initial data release, as trial outcomes will be key in deciding the drug's future in this competitive field.

NMRA-215: Preclinical Challenges in Obesity Treatment

NMRA-215, an oral NLRP3 inhibitor from Neumora Therapeutics (NMRA) for obesity, has a low PoA of 4%. In preclinical stages, NMRA-215 has shown promising weight loss in mouse models, but the absence of human clinical data raises questions about its potential efficacy and safety. The obesity market is expected to hit $33.5 billion by 2030, yet it's crowded with established therapies. The start of Phase 1 trials in Q1 2026 and the subsequent 12-week proof-of-concept data will be crucial for NMRA-215's future. Investors should be cautious, as moving from preclinical promise to human efficacy is challenging, and the drug must stand out in a market dominated by effective GLP-1/GIP therapies.

The bottom line

Investors should keep a close eye on these biotech catalysts and the developments that could change the market landscape.